2seventy slides on latest roadblock for cancer drug

The cancer-focused spinout of bluebird bio Inc. has hit another roadblock for its cancer drug, Abecma — the company's only approved product.

Previous SteelFusion Clinical Toxicology Laboratory files for Chapter 11 bankruptcy protection
Next New Atlanta tech company CEO sees growth in solving ‘massive problem’ for health care companies